Skip to contentB
BIO-TECHNE Corp
B
TECHBIO-TECHNE Corp Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$306.10M$306.10Mderived+1.6% vs Q4 2023 Net Income$40.59M$40.59Mderived−46.2% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BIO-TECHNE Corp · CIK 842023 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$203,348,000−0.7% Operating Incomederived$45,822,000−51.5% Operating Cash Flowderived$75,496,000−9.5% Free Cash Flowderived$57,516,000−20.7% Margins · derivedGross margin66.4%−1.5 pt vs Q4 2023
Operating margin15.0%−16.4 pt vs Q4 2023
Net margin13.3%−11.8 pt vs Q4 2023
ended Jun 30, 2024 · filed Aug 22, 2024 · 53 d after period end